Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

TARS

Tarsus Pharmaceuticals Inc

Dec 12 • 04:00PM ET

51.08

Dollar change -1.06
Percentage change -2.03	%

Healthcare • Biotechnology • USA • NASD

Peers: XENE FOLD RDUS VKTX SRPT AXSM BTAI PRTA APLT PTCT

| Held by: IWM VTI VXF IWO IBB SCHA PJP VTWO XPH IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.81	Insider Own	14.76%	Shs Outstand	38.20M	Perf Week	1.51%
Market Cap	1.95B	Forward P/E	-	EPS next Y	-1.81	Insider Trans	-0.80%	Shs Float	32.58M	Perf Month	7.38%
Income	-134.34M	PEG	-	EPS next Q	-0.77	Inst Own	109.14%	Short Float	22.04%	Perf Quarter	53.58%
Sales	129.62M	P/S	15.06	EPS this Y	29.83%	Inst Trans	12.10%	Short Ratio	10.29	Perf Half Y	54.13%
Book/sh	6.22	P/B	8.22	EPS next Y	44.24%	ROA	-41.68%	Short Interest	7.18M	Perf Year	183.46%
Cash/sh	8.29	P/C	6.16	EPS next 5Y	-	ROE	-59.56%	52W Range	17.45 - 54.44	Perf YTD	152.25%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-132.82%	ROI	-43.45%	52W High	-6.17%	Beta	1.05
Dividend TTM	-	Quick Ratio	5.38	Sales past 5Y	-17.43%	Gross Margin	92.97%	52W Low	192.72%	ATR (14)	2.48
Dividend Ex-Date	-	Current Ratio	5.42	EPS Y/Y TTM	0.54%	Oper. Margin	-108.47%	RSI (14)	60.34	Volatility	5.16% 5.29%
Employees	244	Debt/Eq	0.30	Sales Y/Y TTM	801.96%	Profit Margin	-103.64%	Recom	1.30	Target Price	65.33
Option/Short	Yes / Yes	LT Debt/Eq	0.30	EPS Q/Q	52.27%	Payout	-	Rel Volume	0.90	Prev Close	52.14
Sales Surprise	11.43%	EPS Surprise	35.09%	Sales Q/Q	2471.78%	Earnings	Nov 13 AMC	Avg Volume	697.86K	Price	51.08
SMA20	3.76%	SMA50	16.16%	SMA200	48.28%	Trades		Volume	747,057	Change	-2.03%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-20-23	Initiated	Goldman	Neutral	$19
Jul-18-23	Initiated	William Blair	Outperform	$44
May-18-23	Initiated	Guggenheim	Buy
Aug-01-22	Initiated	Barclays	Overweight	$40
Dec-21-21	Initiated	H.C. Wainwright	Buy	$40
Nov-23-21	Initiated	Oppenheimer	Outperform	$55
Nov-10-20	Initiated	Raymond James	Strong Buy	$39
Nov-10-20	Initiated	Ladenburg Thalmann	Buy	$42
Nov-10-20	Initiated	Jefferies	Buy	$35
Nov-10-20	Initiated	BofA Securities	Buy	$33

Dec-04-24 09:55AM	Wall Street Analysts Think Tarsus Pharmaceuticals (TARS) Could Surge 26.98%: Read This Before Placing a Bet (Zacks)
Nov-18-24 09:55AM	Wall Street Analysts Believe Tarsus Pharmaceuticals (TARS) Could Rally 41.09%: Here's is How to Trade (Zacks)
Nov-14-24 02:15AM	Tarsus Pharmaceuticals Inc (TARS) Q3 2024 Earnings Call Highlights: Record Sales and Strategic ... (GuruFocus.com)
Nov-13-24 05:30PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements (GlobeNewswire)
08:30AM	Loading…
08:30AM	Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors (GlobeNewswire)
Nov-07-24 10:00AM	Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Nov-06-24 04:30PM	Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024 (GlobeNewswire)
Nov-05-24 08:30AM	Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer (GlobeNewswire)
Oct-30-24 06:39AM	Tarsus Pharmaceuticals (TARS) Surges 10.6%: Is This an Indication of Further Gains? (Zacks)
Oct-17-24 08:30AM	Tarsus Launches Your Mitey Problem, the First Direct-to-Consumer TV Campaign for XDEMVY (lotilaner ophthalmic solution) 0.25% (GlobeNewswire)
Oct-09-24 05:56PM	Tarsus Pharmaceuticals Inc (TARS) Q2 2024 Earnings Call Highlights: Robust Sales Growth and ... (GuruFocus.com)
Sep-25-24 05:00PM	Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024 (GlobeNewswire)
Aug-28-24 05:00PM	Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference (GlobeNewswire)
Aug-08-24 09:56PM	TARS Stock Earnings: Tarsus Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace) +13.72%
06:05PM	Loading…
06:05PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements (GlobeNewswire)
Jul-29-24 04:30PM	Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024 (GlobeNewswire)
May-29-24 05:00PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-09-24 05:00PM	Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference (GlobeNewswire) -8.86% +8.70%
12:48PM	Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q1 2024 Earnings Call Transcript (Insider Monkey)
11:06AM	Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $61 From $59, Maintains Outperform Rating (MT Newswires)
03:49AM	Tarsus Pharmaceuticals Inc (TARS) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth ... (GuruFocus.com)
May-08-24 08:58PM	TARS Stock Earnings: Tarsus Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:40PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements (GlobeNewswire)
May-06-24 09:55AM	Does Tarsus Pharmaceuticals (TARS) Have the Potential to Rally 38.7% as Wall Street Analysts Expect? (Zacks)
May-01-24 05:00PM	Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024 (GlobeNewswire) +6.59%
Apr-23-24 08:30AM	Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon (GlobeNewswire)
Apr-09-24 07:35AM	5 Best Biotech ETFs To Buy (Insider Monkey)
09:55AM	Loading…
Apr-08-24 09:55AM	Wall Street Analysts Predict a 47.12% Upside in Tarsus Pharmaceuticals (TARS): Here's What You Should Know (Zacks)
Apr-04-24 11:33AM	Aggressive Stock Portfolio: 13 Stocks Picked by Analysts (Insider Monkey)
Apr-01-24 12:00PM	Tarsus Pharmaceuticals (TARS) Upgraded to Buy: Here's Why (Zacks)
Mar-06-24 09:55AM	How Much Upside is Left in Tarsus Pharmaceuticals, Inc. (TARS)? Wall Street Analysts Think 37.91% (Zacks)
Mar-05-24 04:30PM	Tarsus to Participate at Upcoming Investor Conferences (GlobeNewswire)
08:30AM	Tarsus Introduces Mite Party Campaign for XDEMVY (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis (GlobeNewswire)
Mar-01-24 12:07AM	Tarsus Announces Pricing of $100.0 Million Public Offering (GlobeNewswire)
Feb-29-24 04:37PM	Tarsus Announces Proposed $100.0 Million Public Offering (GlobeNewswire)
Feb-28-24 12:00PM	Here's Why Tarsus Pharmaceuticals, Inc. (TARS) is a Great Momentum Stock to Buy (Zacks)
09:58AM	Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 11:13PM	Q4 2023 Tarsus Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +18.28%
06:34AM	Tarsus Pharmaceuticals Inc (TARS) Reports Robust Q4 and Full-Year 2023 Financial Results (GuruFocus.com)
06:00AM	Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements (GlobeNewswire)
Feb-22-24 08:00AM	Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept Tick-Kill Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease (GlobeNewswire)
Feb-20-24 05:00PM	Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024 (GlobeNewswire)
Jan-31-24 05:00PM	Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference (GlobeNewswire) +6.17%
Jan-30-24 04:06AM	Tarsus Pharmaceuticals, Inc. (TARS) Moves 8.5% Higher: Will This Strength Last? (Zacks)
Jan-21-24 07:01AM	11 Stocks That Will Make You Rich in 5-10 Years (Insider Monkey)
Dec-21-23 03:32PM	Tarsus Pharmaceuticals Stock Scores Relative Strength Rating Upgrade (Investor's Business Daily)
Dec-11-23 08:00AM	Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites (GlobeNewswire)
Dec-01-23 11:04PM	Insider Sell Alert: Tarsus Pharmaceuticals Inc's Dianne Whitfield Offloads 8,355 Shares (GuruFocus.com)
Nov-12-23 12:15PM	Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 04:05PM	Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements (GlobeNewswire) -5.86% +12.20%
Nov-01-23 06:35PM	Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023 (GlobeNewswire)
Sep-06-23 08:00AM	Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY, the First and Only FDA Approved Treatment for Demodex Blepharitis (GlobeNewswire)
Aug-30-23 04:30PM	Tarsus to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-28-23 10:22AM	15 Most Shorted Stocks That Are Loved By Analysts (Insider Monkey)
Aug-24-23 09:00AM	Now Available XDEMVY (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis (GlobeNewswire)
Aug-10-23 04:05PM	Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements (GlobeNewswire)
Aug-03-23 02:14PM	This Tarsus Pharmaceuticals Insider Increased Their Holding In The Last Year (Simply Wall St.)
Aug-01-23 10:30PM	Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock (GlobeNewswire) -16.99% -5.53%
Jul-31-23 04:29PM	Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock (GlobeNewswire)
Jul-25-23 07:00AM	FDA Approves XDEMVY (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis (GlobeNewswire) -24.82%
Jul-20-23 02:04PM	Why Shares of Tarsus Pharmaceuticals Are Up Thursday (Motley Fool) +15.56%
Jul-19-23 08:34PM	Tarsus Pharmaceuticals, Inc. (TARS) Surges 7.8%: Is This an Indication of Further Gains? (Zacks) +7.83%
10:13AM	Oppenheimer Says These 2 Stocks Could Double Your Money Heres Why They Could Jump (TipRanks)
Jun-12-23 08:30AM	Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis (GlobeNewswire)
Jun-05-23 08:30AM	Tarsus to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-09-23 04:05PM	Tarsus Reports First Quarter 2023 Financial Results and Recent Business Achievements (GlobeNewswire)
May-08-23 08:30AM	Tarsus Launches Dont Freak Out. Get Checked Out. Campaign During Healthy Vision Month to Encourage Patients with Demodex Blepharitis to Visit Eye Care Providers (GlobeNewswire)
May-05-23 08:22AM	Shareholders Should Be Pleased With Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Price (Simply Wall St.)
May-03-23 04:30PM	Tarsus to Participate at the Bank of America 2023 Healthcare Conference (GlobeNewswire)
Apr-24-23 08:30AM	Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer (GlobeNewswire)
Apr-18-23 06:04AM	Tarsus Pharmaceuticals, Inc. (TARS) Soars 8.6%: Is Further Upside Left in the Stock? (Zacks) +5.25%
Apr-06-23 03:52PM	Shareholders in Tarsus Pharmaceuticals (NASDAQ:TARS) are in the red if they invested a year ago (Simply Wall St.)
Mar-17-23 06:28AM	Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Is Expected To Breakeven In The Near Future (Simply Wall St.)
Mar-13-23 04:05PM	Tarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements (GlobeNewswire)
Mar-09-23 10:00AM	Will Provention Bio, Inc. (PRVB) Report Negative Earnings Next Week? What You Should Know (Zacks)
Mar-02-23 04:30PM	Tarsus to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-24-23 11:44AM	Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insiders placed bullish bets worth US$1.6m in the last 12 months (Simply Wall St.)
Jan-24-23 04:33AM	Strength Seen in Tarsus Pharmaceuticals, Inc. (TARS): Can Its 5.0% Jump Turn into More Strength? (Zacks)
Dec-16-22 07:00AM	Tarsus Added to NASDAQ Biotechnology Index (GlobeNewswire)
Dec-15-22 12:45PM	Tarsus Pharma Touts Positive Data For Experimental Drug For Tick-Borne Disease (Benzinga)
08:30AM	Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease (GlobeNewswire)
Dec-08-22 06:55AM	Institutional investors own a significant stake of 41% in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) (Simply Wall St.)
Nov-11-22 06:03AM	Tarsus Pharmaceuticals Third Quarter 2022 Earnings: US$0.84 loss per share (vs US$0.76 loss in 3Q 2021) (Simply Wall St.)
Nov-09-22 08:45AM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Tarsus Reports Third Quarter 2022 Financial Results and Recent Business Achievements (GlobeNewswire)
Oct-25-22 08:30AM	Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meeting (GlobeNewswire)
Oct-17-22 09:26AM	Tarsus Pharmaceuticals (NASDAQ:TARS) investors are sitting on a loss of 40% if they invested a year ago (Simply Wall St.)
Oct-11-22 08:30AM	Tarsus Announces Transition Plans for Board of Directors (GlobeNewswire)
Oct-06-22 08:30AM	Tarsus Appoints Scott Morrison as Board Member and Audit Committee Chair (GlobeNewswire)
Sep-29-22 08:30AM	Tarsus Launches Look at the Lids Campaign to Encourage Eye Care Professionals to Identify and Diagnose Demodex Blepharitis (GlobeNewswire)
Sep-27-22 12:00PM	Tarsus to Present Saturn-2 Pivotal Phase 3 Trial Data and Saturn-1 Extension Study Long-Term Safety Data Evaluating TP-03 for the Treatment of Demodex Blepharitis at Upcoming Eye Care Meetings (GlobeNewswire)
Sep-17-22 10:23AM	The Chief Medical Advisor & Director of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), Elizabeth Lin, Just Bought A Few More Shares (Simply Wall St.)
Sep-07-22 07:00AM	Tarsus Submits New Drug Application to the FDA for TP-03 for the Treatment of Demodex Blepharitis (GlobeNewswire)
Aug-11-22 05:25PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +6.81%
04:05PM	Tarsus Reports Second Quarter 2022 Financial Results and Recent Business Achievements (GlobeNewswire)
Aug-05-22 08:30AM	Tarsus Initiates Phase 2a Ersa Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease (GlobeNewswire)
Jul-25-22 08:00AM	Certara Appoints Rosemary Crane as New Independent Board Member (GlobeNewswire)

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LINK WILLIAM J PHD	Director	Aug 12 '24	Sale	26.08	35,000	912,961	0	Aug 14 04:34 PM
FLYING L PARTNERS XI LLC	Director	Aug 12 '24	Proposed Sale	26.85	35,000	939,750		Aug 12 04:25 PM
Farrow Jeffrey S	See Remarks	Jun 18 '24	Sale	27.47	10,445	286,924	18,136	Jun 20 04:26 PM
Mottiwala Aziz	Chief Commercial Officer	Mar 18 '24	Sale	30.60	4,766	145,840	54,075	Mar 19 07:08 PM
Wahl Bryan	General Counsel	Mar 18 '24	Sale	30.60	4,436	135,742	40,951	Mar 19 07:05 PM
Azamian Bobak R.	President/CEO and Board Chair	Mar 18 '24	Sale	30.60	10,415	318,699	26,456	Mar 19 07:05 PM
Whitfield Dianne C.	Chief Human Resources Officer	Mar 18 '24	Sale	30.60	4,314	132,008	34,181	Mar 19 07:04 PM
Neervannan Seshadri	Chief Operating Officer	Mar 18 '24	Sale	30.60	4,879	149,297	64,767	Mar 19 07:03 PM
Azamian Bobak R.	President/CEO and Board Chair	Dec 27 '23	Sale	20.22	8,000	161,760	830,106	Dec 29 05:08 PM
Trevejo Jose M.	CHIEF MEDICAL OFFICER	Dec 20 '23	Sale	20.00	2,252	45,040	2,251	Dec 22 05:32 PM
Azamian Bobak R.	President/CEO and Board Chair	Dec 20 '23	Sale	20.27	40,000	810,623	838,106	Dec 22 05:30 PM
Goldberg Andrew D.	Director	Dec 15 '23	Buy	18.96	1,000	18,960	3,000	Dec 19 06:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TARS

Tarsus Pharmaceuticals Inc

Upgrade your FINVIZ experience